Dr. Huseyin Naci is an Assistant Professor of Health Policy.
Huseyin’s academic interests include research design, comparative effectiveness research, drug regulation, and health policy evaluation. His methodological research focuses on the strengths and weaknesses of study designs in determining the benefits and harms of health care interventions and policies. He is particularly interested in the application of evidence generated from randomized trials, observational studies, and network meta-analyses to decision-making in health policy and clinical practice.
Huseyin’s policy-relevant research focuses on the unintended consequences of health policies; market entry requirements for new health technologies; economic access to medications; and the role of health care professionals in caring for individuals with multiple chronic conditions.
Prior to starting his research at LSE Health, Huseyin conducted research in the areas of international health, mental health, and international development at the World Health Organization and Johns Hopkins University. Most recently, he was a Thomas O. Pyle Fellow in Population Medicine at Harvard University (2013-2014) and a Fellow in Pharmaceutical Policy Research at Harvard Medical School and Harvard Pilgrim Health Care Institute (2012-2013), both in Boston, USA.
Huseyin received his Doctor of Philosophy (PhD) in Pharmaceutical Policy and Economics from the London School of Economics and & Political Science (London, UK); his Master of Science in Public Health (MSPH) degree in International Health, with a focus on Health Economics from the Johns Hopkins University Bloomberg School of Public Health (Baltimore, MD, USA); and his Bachelor of Arts degree in Biochemistry from Knox College (Galesburg, IL, USA).
Harvard University Thomas O. Pyle Fellowship in Population Medicine (2013-2014)
Harvard Medical School Fellowship in Pharmaceutical Policy Research (2012-2013)
Delta Omega, Alpha Chapter – United States National Honor Society for Public Health (2008)
Cyprus Fulbright Commission – Cyprus-America Scholarship Program Full Recipient (2006-2008)
Naci H, Ioannidis JPA. Evaluation of Wellness Determinants and Interventions by Citizen Scientists. JAMA. 2015
Tervonen T, Naci H, van Valkenhoef G, Ades AE, Angelis A, Hillege HL, Postmus D. Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment: Choosing Among Statins in Primary Prevention. Medical Decision Making. 2015
Naci H, Dias S, Ades AE. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol lowering in statin trials. BMJ. 2014
Naci H, Ioannidis JPA. How Good Is "Evidence" from Clinical Studies of Drug Effects and Why Might Such Evidence Fail in the Prediction of the Clinical Utility of Drugs? Annual Reviews of Pharmacology and Toxicology. 2015
Naci H, Soumerai SB, Ross-Degnan D, Zhang F, Briesacher BA, Gurwitz JH, Madden JM. Medication affordability gains following medicare part d are eroding among elderly with multiple chronic conditions. Health Affairs. 2014
Naci H, Ioannidis JPA. Comparative Effectiveness of Exercise and Drug Interventions on Mortality Outcomes: Meta-epidemiological Study. BMJ. 2013
Naci H, Brugts J, Ades T. Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-analysis of 246,955 Participants from 135 Randomized, Controlled Trials. Circulatio: Cardiovascular Quality and Outcomes. 2013
Jansen JP, Naci H. Is Network Meta-Analysis as Valid as Standard Pairwise Meta-Analysis? It All Depends on the Distribution of Effect Modifiers. BMC Medicine. 2013
Mossialos E, Naci H, Courtin E. Expanding the role of community pharmacists: Policymaking in the absence of policy-relevant evidence? Health Policy. 2013
Naci H, Brugts JJ, Tsoi B, Toor H, Fleurence R, Ades AE. Comparative Benefits of Statins in Primary and Secondary Prevention of All-cause Mortality and Major Coronary Events: A meta-analysis of placebo-controlled and active-comparator trials. European Journal of Preventive Cardiology. 2013
Naci H, Cylus JC, Sato A, Vandoros S, Perampaladas K. Raising the bar for market authorization. BMJ. 2012
Chisholm D, Naci H, Hyder AA, Tran N, Peden M. Cost effectiveness of strategies to combat road traffic injuries in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ. 2012
Sorenson C, Naci H, Cylus JD, Mossialos EA. Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ. 2011
Fleurence R, Naci H, Jansen JP. The Critical Role of Observational Evidence in Comparative Effectiveness Research. Health Affairs. 2010